Stockreport

Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 [Yahoo! Finance]

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF achieving onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours, and confirming its potentially differentiated profile for the treatment o [Read more]